A rare thyroid cancer causes more than half of all deaths from thyroid cancer, yet makes up only a small fraction of cases. This review asks whether the answer is to target the cancer’s weak spots, awaken the immune system, or combine both. Anaplastic thyroid cancer is rare and aggressive.

It causes more than half of all deaths from thyroid cancer, even though it accounts for only about two percent of thyroid cancers. The usual options are surgery, radiation, and chemotherapy, yet the review begins from a hard problem: there are currently no effective treatments for this condition.

The search has moved toward targeted treatment, which acts on genetic changes and molecular pathways linked to tumor progression. Immunotherapy has also emerged as a promising treatment for treating anaplastic thyroid cancer, although it remains in the experimental stage.

A useful everyday picture is a locked building. Targeted treatment tries the key that fits one faulty lock; immunotherapy tries to help the security team recognize and remove the intruder. Anaplastic thyroid cancer can be driven by two connected internal growth routes, affecting blood-vessel formation, cell multiplication, and tumor growth.

The important point is that treatments can interrupt these routes at several points, from incoming growth signals to the machinery controlling the cell’s nucleus. One targeted combination produced a striking result in advanced cancer carrying a particular change: eleven patients went into remission in the preliminary results.

That activity led to FDA approval of dabrafenib plus trametinib for patients with anaplastic thyroid cancer whose tumors carry that BRAF alteration. A different targeted combination also produced a partial remission in one patient whose cancer did not carry the BRAF mutation, suggesting the search may extend beyond one genetic route.

Immunotherapy works differently. One drug targets a brake on immune cells, blocking that brake so the cells can attack cancer more effectively. In a clinical trial, nineteen percent of patients had their cancer respond, including complete and partial remissions.

The review says this confirmed activity and safety in patients with advanced disease and short life expectancy. The strongest idea in the review is not necessarily choosing one side. In patients with anaplastic thyroid cancer, combining an immune treatment with a targeted treatment delayed disease progression, although half of the patients experienced adverse effects.

Another study found that adding immune treatment early during progression, or during treatment with a kinase-blocking drug, could improve the effect of those drugs to some extent. More combination studies are still underway. Across these experimental groups, combining immunotherapy with targeted therapy was more effective than either treatment alone, although few clinical experiments exist and further research is needed.

But the clinical evidence is still limited, and further research is needed. The catch is that combining treatments can also combine their harms. Toxicity is the biggest limitation of combination immunotherapy, and it becomes more serious with some immune-drug combinations.

Doctors also need to choose the right order and timing. The review calls for markers that can predict which treatment will suit each patient, so the immune system can be used more effectively without adding unnecessary harm. The review points toward treatment matched to each patient: targeted drugs can work when the cancer carries a particular change, while immune treatment and combinations may help more.

But side effects and limited evidence still demand caution.